Advertisement

Topics

Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy

08:00 EDT 5 Jul 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
— Trial Will Augment Ongoing Phase 3 PALISADE Trial and Explore Endpoint of Tolerating at Least 1000-mg Dose of Peanut Protein to Support AR101 Regulatory Filings in Europe — Aimmune Therapeutics, Inc. (Nasdaq:AIMT), tod...

Other Sources for this Article

Aimmune Therapeutics, Inc.
Investors
Laura Hansen, Ph.D., 650-396-3814
lhansen@aimmune.com
or
Media
Stephanie Yao, 650-351-6479
syao@aimmune.com

NEXT ARTICLE

More From BioPortfolio on "Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...